This video is featured in the 2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Avelumab in Early TNBC With Residual Disease After Neoadjuvant Chemo or at High Risk After Primary Surgery and Adjuvant Chemo"

70 views
July 2, 2024
Comments 0
Login to view comments. Click here to Login